Sources say FDA commissioner sought rejection of KalVista’s uncommon illness drug; FDA appears into Sarepta’s Duchenne remedy after deaths; and extra

Welcome again to Endpoints Weekly! Thanks for spending your Saturday with us. We begin this week’s recap with reporting from Endpoints Information’ senior biopharma correspondent Andrew Dunn on the FDA’s evaluate of KalVista Prescribed drugs’ uncommon …